NeuroPace Announces 3-Year PAS Results and NAUTILUS Presentation at AAN 2026
NeuroPace, Inc. has published 3-year results from its RNS® System Post-Approval Study (PAS) in Neurology, marking a significant milestone in its clinical evidence program. Additionally, the company presented 12- and 18-month data from its ongoing NAUTILUS trial at the 2026 American Academy of Neurology Annual Meeting, focusing on improving treatments for individuals with drug-resistant epilepsy.
MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with drug resistant epilepsy, today announced a major milestone in its clinical evidence program with the publication of 3-year results from the RNS® System Post-Approval Study (PAS) in Neurology, alongside the Company’s recent presentation of 12- and 18-month data from its ongoing NAUTILUS trial at the 2026 American Academy of Neurology Annual Meet